Table 2.
IVT-AFL injections and visits over 12 and 24 months of treatment
| Overall population (FAS; n = 514) | Regular cohort (n = 102) | Irregular cohort with initial doses (n = 268) | Irregular cohort without initial doses (n = 60) | |
|---|---|---|---|---|
| IVT-AFL injections | ||||
| Mean (SD) over 12 Months | 6.0 (2.1) | 7.2 (0.8) | 6.1 (2.2) | 5.2 (1.8) |
| Mean (SD) over 24 Months | 8.8 (4.3) | 10.6 (2.8) | 9.3 (4.6) | 7.8 (3.7) |
| Min; max | 1.0; 23.0 | 6.0; 17.0 | 3.0; 23.0 | 1.0; 16.0 |
| Median | 8.0 | 11.0 | 9.0 | 8.0 |
| Q1; Q3 | 5.0; 12.0 | 8.0; 13.0 | 5.0; 12.0 | 4.0; 11.0 |
| Visits | ||||
| Mean (SD) over 12 Months | 9.3 (2.3) | 9.5 (1.8) | 10.1 (1.9) | 8.8 (1.8) |
| Mean (SD) over 24 Months | 15.1 (5.1) | 15.9 (4.2) | 16.8 (4.2) | 14.8 (3.8) |
| Min; max | 2.0; 29.0 | 8.0; 27.0 | 6.0; 29.0 | 6.0; 23.0 |
| Median | 15.0 | 16.0 | 17.0 | 15.0 |
| Q1; Q3 | 12.0; 19.0 | 13.0; 19.0 | 14.0; 20.0 | 12.0; 17.0 |
FAS full analysis set, IVT-AFL intravitreal aflibercept, n n numbers from the overall FAS population, Q1;Q3, interquartile range, SD standard deviation